A study for the suppressive effect of mulberry leaf powder-containing foods on the elevation of postprandial blood glucose level.

A study for the suppressive effect of mulberry leaf powder-containing foods on the elevation of postprandial blood glucose level. - A study for the suppressive effect of mulberry leaf powder-containing foods on the elevation of postprandial blood glucose level.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039508

Enrollment

Registered

2021-04-16

Start date

2020-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Intake of test food (single ingestion)-washing out (7 days or more)-intake of placebo (single ingestion) Intake of placebo (single ingestion)-washing out (7 days or more)-intake of test food (single i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Healthy males and females from 20 to 64 years of age (2) Blood glucose level at postprandial 30 minitues is ranged from 140 mg/dL to 199 mg/dL

Exclusion criteria

Exclusion criteria: (1) Subjects who have a habit of continuously ingesting mulberry (including mulberry tea). (2) Subjects who routinely take foods or medicines affecting the test result. (3) Subjects who have a disease requiring regular medication. (4) Subjects who are under treatment or have a history of serious disease (e.g., diabetes, liver disease, kidney disease, or heart disease). (5) Ineligible subjects with abnormal laboratory value or cardiopulmonary function. (6) Subjects having possibilities for emerging allergy related to the study. (7) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on preliminary examination. (8) Subjects who have habits affecting research results, such as doing shift work day and night, or Subjects who have a plan that affect research results such as day and night shift work and overseas. (9) Subjects who have participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study. (10) Females who are known or suspected to be pregnant, breastfeeding or desire to become pregnant during the trial period. (11) Subjects judged as unsuitable for the study by the investigator for other reasons.

Design outcomes

Primary

Measure	Time frame
Area under the curve of blood glucose level	—

Secondary

Measure	Time frame
Fasting blood glucose level Postprandial blood glucose level (30, 60, 90, 120 min) maximum blood glucose level Fasting blood insulin level Postprandial blood insulin level (30, 60, 90, 120 min)	—

Countries

Japan

Contacts

Public ContactShingo Yamamichi

TTC Co., Ltd. Clinical Research Planning Department

s.yamamichi@ttc-tokyo.co.jp03-5459-5329

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026